Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study (Q34629714)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study (English)

1 reference

Europe PubMed Central

3 August 2017

multicenter clinical trial

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Matthew R Smith

1

1 reference

Europe PubMed Central

3 August 2017

S Bruce Malkowicz

2

1 reference

Europe PubMed Central

3 August 2017

Franklin Chu

3

1 reference

Europe PubMed Central

3 August 2017

John Forrest

4

1 reference

Europe PubMed Central

3 August 2017

Paul Sieber

5

1 reference

Europe PubMed Central

3 August 2017

K Gary Barnette

6

1 reference

Europe PubMed Central

3 August 2017

Domingo Rodriquez

7

1 reference

Europe PubMed Central

3 August 2017

Mitchell S Steiner

8

1 reference

Europe PubMed Central

3 August 2017

language of work or name

0 references

publication date

1 April 2008

1 reference

Europe PubMed Central

3 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

3 August 2017

26

1 reference

Europe PubMed Central

3 August 2017

1824-1829

1 reference

Europe PubMed Central

3 August 2017

11

1 reference

Europe PubMed Central

3 August 2017

Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049948

7 July 2018

The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049948

7 July 2018

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049948

7 July 2018

Androgen deprivation therapy for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049948

7 July 2018

Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049948

7 July 2018

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049948

7 July 2018

Cholesterol management in theory and practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049948

7 July 2018

Insulin sensitivity during combined androgen blockade for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049948

26 October 2018

Bone mineral density and lipid changes during 5 years of follow-up in a study of prevention of breast cancer with toremifene in healthy, high-risk pre- and post-menopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049948

26 October 2018

Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049948

26 October 2018

Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049948

26 October 2018

Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049948

26 October 2018

Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049948

26 October 2018

Changes in body composition during androgen deprivation therapy for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049948

26 October 2018

The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049948

26 October 2018

Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18398147

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women

1 reference

https://pubmed.ncbi.nlm.nih.gov/18398147

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective estrogen receptor modulators to prevent treatment-related osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18398147

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18398147

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

1 reference

https://pubmed.ncbi.nlm.nih.gov/18398147

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18398147

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18398147

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2007.13.5517

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34629714&oldid=1974014188"